Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GGT1 | P19440 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28721112 | 1.00 | DGAT1 (0.39) | DGAT1KDM4ESMN1; SMN2HIF1AGGT1 | |
| SCHEMBL1066622 | 1.00 | DGAT1 (0.39) | DGAT1KDM4ESMN1; SMN2HIF1AGGT1 | |
| SCHEMBL18817843 | 0.89 | DGAT1 (0.43) | DGAT1KDM4E | |
| SCHEMBL7705520 | 0.84 | DGAT1 (0.41) | DGAT1KDM4ESMN1; SMN2GGT1MEN1 | |
| SCHEMBL1066048 | 0.84 | DGAT1 (0.41) | DGAT1KDM4ESMN1; SMN2GGT1MEN1 | |
| SCHEMBL1422856 | 0.83 | DGAT1 (0.39) | DGAT1SMN1; SMN2HIF1AGGT1MEN1 | |
| SCHEMBL4366521 | 0.83 | DGAT1 (0.39) | DGAT1SMN1; SMN2HIF1AGGT1MEN1 | |
| SCHEMBL4366519 | 0.83 | DGAT1 (0.39) | DGAT1SMN1; SMN2HIF1AGGT1MEN1 | |
| SCHEMBL3286466 | 0.83 | DGAT1 (0.39) | DGAT1SMN1; SMN2HIF1AGGT1MEN1 | |
| SCHEMBL5498917 | 0.82 | DGAT1 (0.52) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119101187-A | Antibacterial peptide and application thereof | 北京化工大学 | 2024-12-10 | — | — | CN | claimed |
| EP-1506970-A1 | COMPOUNDS WHICH CAN BLOCK THE RESPONSE TO CHEMICAL SUBSTANCES OR THERMAL STIMULI OR MEDIATORS OF INFLAMMATION OF NOCICEPTORS, PRODUCTION METHOD THEREOF AND COMPOSITIONS CONTAINING SAME | Diverdrugs, S.L. (ES) | 2005-02-16 | — | — | EP | claimed |
| US-6590061-B1 | Synthetic polypeptide or peptides having narrow molecular weight distribution used as telechelic polymers for synthesis of block or graft copolymers | INSTITUTE OF MACROMOLECULAR CHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-07-08 | — | — | US | claimed |
| EP-1088020-B1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE (CZ) | 2002-12-18 | — | — | EP | claimed |
| EP-1088020-A1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) | 2001-04-04 | — | — | EP | claimed |
| WO-1999064495-A1 | FUNCTIONALISED POLYMERS OF α-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) | 1999-12-16 | — | — | WO | claimed |
| CN-119101187-A | Antibacterial peptide and application thereof | 北京化工大学 | 2024-12-10 | — | — | CN | disclosed |
| US-20240374585-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | REIN THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118510547-A | Targeted linear conjugates comprising polyethylenimine and polyethylene glycol and polymer complexes comprising the same | 塔尔格免疫治疗有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-117940407-A | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX生物治疗股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023283639-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | LUNG THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| CN-109020961-A | Antiviral compound | 吉利德制药有限责任公司 | 2018-12-18 | — | — | CN | disclosed |
| CN-104230900-B | Antiviral compound | 吉利德制药有限责任公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-1246850-A | 1,5-benzodiazepine derivatives | ZERIA PHARM CO LTD (JP) | 2000-03-08 | — | — | CN | disclosed |
| WO-1999064426-A1 | HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0896003-A1 | Peptides for reducing or inhibiting bone resorption, angiogenesis and restenosis | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1999-02-10 | — | — | EP | disclosed |
| EP-0832076-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0755408-A1 | PEPTIDES FOR REDUCING OR INHIBITING BONE RESORPTION, ANGIOGENESIS AND RESTENOSIS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028426-A2 | PEPTIDES FOR REDUCING OR INHIBITING BONE RESORPTION, ANGIOGENESIS AND RESTENOSIS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1993012138-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | SCHERING CORPORATION (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374585-A1 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | CFTR, SCNN1G, SCNN1B | DGAT1 2265/4885KDM4E 4326/4885SMN1; SMN2 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.